Discover more insights into Odyssey Outcomes

Keywords frequently search together with Odyssey Outcomes

Narrow sentence examples with built-in keyword filters

Odyssey Outcomes sentence examples within acute coronary syndrome



Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.



REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL


Odyssey Outcomes sentence examples within kexin type 9



Diabetic outcomes: Cardiovascular outcomes with lipid modification H2D



Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology.


Odyssey Outcomes sentence examples within odyssey outcomes trial



PATIENTS WITH ACUTE CORONARY SYNDROME, ELEVATED ATHEROGENIC LIPOPROTEINS, AND PRIOR CORONARY ARTERY BYPASS GRAFTING DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL



Cardiovascular events with PCSK9 inhibitors: an updated meta‐analysis of randomised controlled trials



Learn more from Odyssey Outcomes


Odyssey Outcomes sentence examples within odyssey outcomes compared



REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL



Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis


Odyssey Outcomes sentence examples within odyssey outcomes study



PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies



[Improvement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board].


More Odyssey Outcomes sentence examples
10.1016/S0735-1097(19)30639-4

PATIENTS WITH ACUTE CORONARY SYNDROME, ELEVATED ATHEROGENIC LIPOPROTEINS, AND PRIOR CORONARY ARTERY BYPASS GRAFTING DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL


More Odyssey Outcomes sentence examples
10.1016/j.jacc.2019.03.013

Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial.


More Odyssey Outcomes sentence examples
10.1016/S2213-8587(19)30158-5

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial



Alirocumab for low-density lipoprotein cholesterol lowering.


More Odyssey Outcomes sentence examples
10.1016/S2213-8587(19)30158-5

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.



High intensity lipid‐lowering therapy after acute coronary syndromes: room for improvement


More Odyssey Outcomes sentence examples
10.1093/eurheartj/ehz514

PCSK9 inhibitors: what we know, what we should have understood, and what is to come.


More Odyssey Outcomes sentence examples
10.1177/2047487319840179

The association between lipid-lowering drugs and circulating concentration of PCSK9


More Odyssey Outcomes sentence examples
10.1007/s11883-019-0789-3

Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session


More Odyssey Outcomes sentence examples
10.1016/S0735-1097(19)32640-3

POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES


More Odyssey Outcomes sentence examples
10.1093/eurheartj/ehz809

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis


More Odyssey Outcomes sentence examples
10.1177/2047487319833504

PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies


More Odyssey Outcomes sentence examples
10.1007/s40256-019-00376-y

Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease



[Improvement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board].


More Odyssey Outcomes sentence examples
10.1016/J.NRLENG.2017.03.005

Cholesterol and stroke: role of PCSK9 inhibitors


More Odyssey Outcomes sentence examples
10.1016/j.atherosclerosis.2019.12.006

Effects of intensive lipid-lowering therapy on mortality after coronary bypass surgery: A meta-analysis of 7 randomised trials.


More Odyssey Outcomes sentence examples
10.20996/1819-6446-2018-14-6-922-934

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial


Learn more from Odyssey Outcomes


Odyssey Outcomes
Encyclopedia